Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
October 3, 2017
BioTime to Present at the Cell and Gene Meeting on the Mesa
ALAMEDA, Calif.--(BUSINESS WIRE)-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases, today announced that Jim Knight, ...
October 3, 2017
AIT Therapeutics’ Inhaled Nitric Oxide Therapy Granted Orphan Drug Designation by the U.S. Food and Drug Administration for Treating Infections Caused by Nontuberculous Mycobacteria (NTM)
REHOVOT, Israel and NEW YORK, Oct. 03, 2017 (GLOBE NEWSWIRE) -- AIT Therapeutics Inc. (AITB), a clinical-stage biopharmaceutical company focused on developing inhaled Nitric Oxide ...
October 3, 2017
Final Results of Albireo’s Phase 2 Study of A4250 in Children with Cholestatic Liver Disease to be Presented at The Liver Meeting® 2017
BOSTON, Oct. 03, 2017 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced ...
October 2, 2017
Onxeo Introduces platON™, a Proprietary Chemistry Platform of Decoy Oligonucleotides
PARIS, Oct. 02, 2017 (GLOBE NEWSWIRE) -- Onxeo S.A. (Euronext Paris:ONXEO) (NASDAQ Copenhagen:ONXEO), (“Onxeo” or the “Company”), a French biotechnology company specializing in the development ...
October 2, 2017
DURECT and Indivior PLC Sign a $17.5 Million Patent Purchase Agreement
CUPERTINO, Calif., Oct. 2, 2017 /PRNewswire/ -- DURECT Corporation (DRRX) today announced a patent purchase agreement with Indivior UK Limited, an affiliate of Indivior PLC (INDV.L), ...
October 2, 2017
Zogenix Announces Proposed Public Offering of 4,300,000 Shares of Common Stock
EMERYVILLE, Calif., Oct. 02, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system ...
October 2, 2017
VBL Therapeutics Announces Positive Outcome in the Third and Final DSMC Review of Phase 3 GLOBE Trial Investigating VB-111 in Recurrent GBM
TEL AVIV, Israel, Oct. 02, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (VBLT), today announced that the independent Data Safety Monitoring Committee (DSMC) met on September ...
October 2, 2017
Kitov Announces Filing by FDA of New Drug Application for KIT-302
TEL AVIV, Israel, October 2, 2017 /PRNewswire/ -- Kitov Pharmaceuticals Holdings Ltd. (NASDAQ: KTOV, TASE: KTOV), an innovative biopharmaceutical company, today announced that the U.S. Food ...
October 2, 2017
Eiger Announces Abstracts and Presentations at the American Association for the Study of Liver Diseases (AASLD) Meeting
PALO ALTO, Calif., Oct. 2, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc., (EIGR) today announced that two abstracts will be presented at the American Association for ...
September 28, 2017
Arrowhead Data Reveal Important Considerations for Future Hepatitis B Treatment
PASADENA, Calif. -- (BUSINESS WIRE) -- Arrowhead Pharmaceuticals Inc. (ARWR) today announced results from studies of ARC-520, a prior-generation RNAi therapeutic candidate against chronic hepatitis B ...
September 28, 2017
Ignyta Announces Updated Data on Entrectinib in ROS1 NSCLC to Be Presented at the IASLC 18th World Conference on Lung Cancer
SAN DIEGO -- (BUSINESS WIRE) -- Ignyta, Inc. (RXDX), a biotechnology company focused on precision medicine in oncology, today announced that updated data on entrectinib – an investigational, ...
September 28, 2017
Alcobra Ltd. and Arcturus Therapeutics, Inc. Agree to Merge
TEL AVIV, Israel, and SAN DIEGO, Sept. 27, 2017 (GLOBE NEWSWIRE) -- Alcobra Ltd. (ADHD) and Arcturus Therapeutics, Inc., a privately held biotechnology company developing ...
September 28, 2017
Basilea announces license agreement for antibiotic Zevtera® (ceftobiprole) with Shenzhen China Resources Gosun Pharmaceutical Co., Ltd.
Basel, Switzerland, September 28, 2017 - Basilea Pharmaceutica Ltd. (BSLN.SW) announced today that Basilea Pharmaceutica International Ltd. (Basilea) has entered into a license agreement with ...
September 28, 2017
Onxeo announces compelling preclinical data in combination for its two innovative compounds, AsiDNA™ and belinostat
PARIS, Sept. 28, 2017 (GLOBE NEWSWIRE) -- Onxeo S.A. (Euronext Paris:ONXEO) (NASDAQ Copenhagen:ONXEO), (“Onxeo” or the “Company”), a French biotechnology company specializing in the development ...
September 28, 2017
VBL Therapeutics to Present at the Chardan Gene Therapy Conference
TEL AVIV, Israel, Sept. 28, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class ...
September 28, 2017
CTD Holdings Enrolls First Patient in US Phase I Clinical Trial of Trappsol(R) Cyclo(TM) for Treatment of Niemann-Pick Disease Type C
ALACHUA, FL--(Marketwired - September 28, 2017) - CTD Holdings, Inc. (CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease ...
September 28, 2017
Albireo Elects Roger Jeffs to Board of Directors
BOSTON, Sept. 28, 2017 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced ...
September 28, 2017
Achaogen Awarded up to $18 Million Contract by BARDA to Support Development of Orally-Administered Antibacterial Candidate C-Scape
SOUTH SAN FRANCISCO, Calif., Sept. 28, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative ...
September 28, 2017
Rockwell Files Calcitriol Post-Approval Manufacturing Submission with FDA
WIXOM, Mich., Sept. 28, 2017 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (RMTI), today provided an update on the commercial launch of Calcitriol, stating that it ...
September 27, 2017
Mateon Therapeutics Announces Termination of FOCUS Study in Ovarian Cancer and Restructuring to Prioritize OXi4503 for AML
SOUTH SAN FRANCISCO, Calif., Sept. 26, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment ...
Page 110 of 138